There were no cases of HER2 positivity among patients with gliomas, sarcomas, small cell lung cancer, gastrointestinal stromal tumors, thyroid carcinoma, uterine sarcoma, thymic carcinoma, and Merkel ...

The universal cell-cycle inhibitor p21Cip1/WAF1 is phosphorylated and localized in the cytoplasm in Her2/neu-overexpressing breast cancers as a result of its physical association with the ...

Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...

Immunohistochemical evaluation of HER2/ neu expression and FISH analysis of HER2 amplification were performed in 320 patients with AOC. Positive HER2 FISH status was found in 20 (6.4%) of the 320 ...

HER2/ neu positivity was assessed using the updated recommendations published by Ellis et al, [12] with IHC 2+ (borderline positivity) corresponding to a weak to moderate complete membrane ...

HER2/neu Expression and Hormonal Therapy in Early Breast Cancer: Can Muddy Waters Become Clear? Authors: Gianluigi Ferretti, Serena Di Cosimo, Diana Giannarelli, Paolo Carlini, Paola Papaldo, Andrea ...

Examples of specific types of immunotherapies include dendritic cell therapy (sipuleucel-T), adoptive T-cell therapy (CAR-T), antibody therapy (anti-CD47, anti-GD2, anti-CD52, anti-PD-L1, anti-SLAMF7, ...

DelveInsight's HER2-low Cancers Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging HER2 ...

DelveInsight's HER2-low Cancers Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging HER2-low ...

HER2/neu primarily activates the MAPK and PI3K pathways, contributing to malignant transformation when overexpressed or amplified.